Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: Reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease

Peter H. O'Donnell, Andrew S. Artz, Samir D. Undevia, Rish K. Pai, Paula Del Cerro, Sarah Horowitz, Lucy A. Godley, John Hart, Federico Innocenti, Richard A. Larson, Olatoyosi M. Odenike, Wendy Stock, Koen Van Besien

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: Reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease'. Together they form a unique fingerprint.

Medicine & Life Sciences